Consensus-interferon and platelet-derived growth factor adversely regulate proliferation and migration of Kaposi's sarcoma cells by control of c-myc expression

American Journal of Pathology

Volumn 149, Issue 6, 1996, Pages 1871-1885

  Köster, Ralf ^a,f   Blatt, Lawrence M ^b   Streubert, Michaela ^a   Zietz, Christian ^c   Hermeking, Heiko ^d   Brysch, Wolfgang ^e   Stürzl, Michael ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b AMGEN INC   (United States)

^c UNIVERSITY OF MUNICH   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e Biognostik GmbH   (Germany)

^f UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR B; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RECOMBINANT PLATELET DERIVED GROWTH FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GROWTH REGULATION; HUMAN; HUMAN CELL; KAPOSI SARCOMA; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SPINDLE CELL;

EID: 0029804583     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Friedman-Kien A: Disseminated Kaposi's sarcoma syndrome in young homosexual men. J Am Acad Dermatol 1981, 5:468-471
2. Safai B, Johnson KG, Myskowski PL, Koziner B, Yang SY, Cunningham-Rundles S, Godbold JH, Dupont B: The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med 1985, 103:744-750
3. Stürzl M, Brandstetter H, Roth WK: Kaposi's sarcoma: a review of gene expression and ultrastructure of KS spindle cells in vivo. AIDS Res Hum Retroviruses 1992, 8:1753-1763
4. Roth WK, Brandstetter H, Stürzl M: Cellular and molecular features of HIV-associated Kaposi's sarcoma. AIDS 1992, 6:895-913
5. Ensoli B, Barillari G, Gallo RC: Pathogenesis of AIDS-associated Kaposi's sarcoma. Hematol Oncol Clin North Am 1991, 5:281-295
6. Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S, Raffeld M, Cafaro A, Chang HK, Brady JN, Gallo RC: Synergy between basic fibroblast growth factor and human immunodeficiency virus type 1 Tat protein in induction of Kaposi's sarcoma. Nature 1994, 321: 674-680
7. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS: Identification of herpesviruslike DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994, 266:1685-1869
8. Stürzl M, Roth WK, Brockmeyer NH, Zietz C, Speiser B, Hofschneider PH: Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi's sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. Proc Natl Acad Sci USA 1992, 89:7046-7050
9. Stürzl M, Brandstetter H, Zietz C, Eisenburg B, Raivich G, Gearing DP, Brockmeyer NH, Hofschneider PH: Identification of interleukin-1 and platelet-derived growth factor-B as major rnitogens for the spindle cells of Kaposi's sarcoma: a combined in vitro and in vivo analysis. Oncogene 1995, 19:2007-2016
10. Roth WK, Werner S, Schirren CG, Hofschneider PH: Depletion of PDGF from serum inhibits growth of AIDS-related and sporadic Kaposi's sarcoma cells in culture. Oncogene 1989, 4:483-487
11. Werner S, Hofschneider PH, Heldin CH, Östman A, Roth WK: Cultured Kaposi's sarcoma-derived cells express functional PDGF A-type and B-type receptors. Exp Cell Res 1990, 187:98-103
12. Lilenbaum RC, Ratner L: Systemic treatment of Kaposi's sarcoma: current status and future directions. AIDS 1994, 8:141-151
13. Stickler MC, Friedman-Kien AE: Kaposi's sarcoma. Clin Dermatol 1991, 9:39-47
14. Reiter Z, Ozes ON, Blatt LM, Stürzl M, Taylor MW: A possible role for interferon-a and activated natural killer cells in remission of AIDS-related Kaposi's sarcoma: in vitro studies. J Acquired Immune Defic Syndr 1992, 5:469-476
15. Singh RK, Gutman M, Bucana CD, Sanchez R, Liansa N, Fiedler IJ: Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995, 92:4562-4566
16. Marcu KB, Bossone SA, Patel AJ: Myc function and regulation. Annu Rev Biochem 1992, 61:809-860
17. Kelly K, Cochran BH, Stiles CD, Leder P: Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 1983, 35:603-610
18. Armelin HA, Armelin MCS, Kelly K, Stewart T, Leder P, Cochran BH, Stiles CD: Functional role for c-myc in mitogenic response to platelet-derived growth factor. Nature 1984, 310:655-660
19. Einat M, Resnitzky D, Kimchi A: Inhibitory effects of Interferon on the expression of genes regulated by platelet-derived growth factor. Proc Natl Acad Sci USA 1985, 82:7608-7612
20. 1 arrest. Nature 1985, 313:597-600
21. Heikkila R, Schwab G, Wickstrom E, Loke SL, Pluznik DH, Watt R, Neckers LM: A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature 1987, 328:445-449
22. Wickstrom EL, Bacon TA, Gonzalez A, Freeman DL, Lyman GH, Wickstrom E: Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide target against c-myc mRNA. Proc Natl Acad Sci USA 1988, 85:1028-1032
23. Bennett MR, Anglin S, McEwan JR, Jargoe R, Newby AC, Evan GI: Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest 1994, 93:820-828
24. Holt JT, Redner RL, Nienhuis AW: An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol Cell Biol 1988, 8:963-973
25. Biro S, Fu YM, Yu ZX, Epstein SE: Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci USA 1993, 90:654-658
26. Roth WK, Werner S. Risau W, Remberger K, Hofschneider PH: Cultured, AIDS-related Kaposi's sarcoma cells express endothelial cell markers and are weakly malignant in vitro, Int J Cancer 1988, 42:767-773
27. Boyden S: The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leukocytes. J Exp Med 1962, 115:453-466
28. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual, ed 2. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1989
29. Persson H, Henninghausen L, Taub R, DeGrado W, Leder P: Molecular genetic characterization of epitopespecific monoclonal antibodies against the Myc family. Science 1984, 225:687-693
30. Ikegaki N, Kennett R: Antibodies to human c-myc oncogene product: evidence of an evolutionary conserved protein induced during cell proliferation. Oncogene 1990, 5:397-403
31. Centers for Disease Control: 1993. Revised classification system for HIV infection and expanded surveilliance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992, 41:1-19
32. Klein ML, Bartley TD, Lai PH, Lu HS: Structural characterization of recombinant consensus interferon-α. J Chromatogr 1988, 454:205-215
33. Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor M: A comparison of interferon-con1 with natural recombinant interferons-α: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res 1992, 12:55-59
34. Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P, Noonan DM, Stetler-Stevenson G: Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants of HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS 1994, 8:1237-1244
35. Chaouchi N, Wallon C, Taieb J, Auffredou MT, Tertian G, Lemoine FM, Delfraissy JF, Vazquez A: Interferon-α-mediated prevention of in vitro apoptosis of chronic lymphocytic leukemia B cells: role of bcl-2 and c-myc. Clin Immunol Immunpathol 1994, 73:197-204
36. Hathorn RW, Tso CL, Kaboo R, Pang S, Figlin R, Sawyers C, deKernion JB, Belldegrun A: In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-α gene transfer. Cancer 1994, 74:1904-1911.
37. Dani C, Mechti N, Piechaczyk M, Lebleu B, Jeanteur P, Blanchard JM: Increased rate of degradation of c-myc mRNA in interferon-treated Daudi cells. Proc Natl Acad Sci USA 1985, 82:4896-4899
38. Womer R, Frick K, Mitchell CD, Ross AH, Bishayee S, Scher CD: PDGF induces c-myc mRNA expression in MG-63 human osteosarcoma cells but does not stimulate cell replication. J Cell Physiol 1987, 132:65-72
39. Ninomya-Tsuji J, Torti FM, Ringold GM: Tumor necrosis factor-induced c-myc expression in the absence of mitogenesis is associated with inhibition of adipocyte differentiation. Proc Natl Acad Sci USA 1993, 90:9611-9615
40. Wagner RW: Gene inhibition using antisense oligodeoxynucleotides. Nature 1994, 372:333-335
41. Burgess TL, Fisher EF, Ross SL, Bready JV, Qian Y-X, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS-F, Kramer TB, Lott FD, Martin FH, Pierce GF, Simonet L, Farrel CL: The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 1995, 92:4051-4055
42. Stürzl M, Cornali E, Blasig C, Bunk D, Schreier A: Growth factors, cytokines, and chemokines in Kaposi's sarcoma. Nouv Dermatol 1966, 15 (suppl 1): 8-14
43. Cornali E, Zietz C, Benelli R, Weninger W, Masiello L, Breier G, Tschachler E, Albini A, Stürzl M: Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 1996, 149:1851-1869